Oncologic Outcomes after Localized Prostate Cancer Treatment: Associations with Pretreatment Prostate Magnetic...

Area of Science:

• Oncology
• Radiology
• Medical Imaging

Background:

• Established prognostic indicators for metastatic disease and prostate cancer survival exist.
• Accurate prognostication is crucial for effective patient management.

Purpose of the Study:

• To determine if T2-weighted magnetic resonance imaging (MRI) findings can enhance existing prognostic models for metastatic disease.
• To assess the impact of T2-weighted MRI on predicting prostate cancer-specific survival.

Main Methods:

• Retrospective analysis of 3,406 men undergoing prostate MRI before treatment (2001-2006).
• MRI exams categorized based on lesion presence and extension (no lesion, organ-confined, extraprostatic extension, seminal vesicle invasion).
• Clinical risk assessed using European Association of Urology (EAU) guidelines and Cancer of the Prostate Risk Assessment (CAPRA) scores. Survival probabilities estimated using Cox models.

Main Results:

• Higher MRI categories correlated with increased risk of metastases (HR 3.5-18.1) and prostate cancer death (HR 3.1-29.7), independent of clinical risk scores.
• Combining MRI categories with EAU or CAPRA scores significantly improved prognostication accuracy for metastases (c-indices increased from ~0.80 to ~0.87).
• Combined MRI and clinical data also enhanced prediction of prostate cancer death (c-indices increased from ~0.81 to ~0.89).

Conclusions:

• T2-weighted MRI findings are linked to long-term oncologic outcomes in localized prostate cancer.
• Integrating MRI data with clinicopathological information offers more precise prognostication.
• This improved accuracy can facilitate tailored management strategies for individual patients.